

SAFETY DATA SHEET



Ezetimibe / Atorvastatin Formulation



Version 5.1 Revision Date: 2023/09/29 SDS Number: 26487-00022 Date of last issue: 2023/04/04
Date of first issue: 2014/10/29

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Ezetimibe / Atorvastatin Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : JL Raya Pandaan KM. 48
Pandaan, Jawa Timur - Indonesia

Telephone : +1-551-430-6000

Emergency telephone number : +1-215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

GHS Classification

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Liver, muscle)

Long-term (chronic) aquatic hazard : Category 2

GHS label elements

Hazard pictograms :

Signal word : Warning

Hazard statements : H373 May cause damage to organs (Liver, muscle) through prolonged or repeated exposure if swallowed.
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**
P260 Do not breathe dust.
P273 Avoid release to the environment.
Response:

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
5.1	2023/09/29	26487-00022	Date of first issue: 2014/10/29

P314 Get medical advice/ attention if you feel unwell.
P391 Collect spillage.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 10 -< 30
Atorvastatin	134523-03-8	>= 10 -< 25
Ezetimibe	163222-33-1	>= 2.5 -< 10
Magnesium stearate	557-04-0	< 10

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.
Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May cause damage to organs through prolonged or repeated exposure if swallowed.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
5.1	2023/09/29	26487-00022	Date of first issue: 2014/10/29

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Fluorine compounds
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Ezetimibe / Atorvastatin Formulation

Version 5.1 Revision Date: 2023/09/29 SDS Number: 26487-00022 Date of last issue: 2023/04/04
Date of first issue: 2014/10/29

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labelled containers.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	NAB	10 mg/m ³	ID OEL
		TWA	10 mg/m ³	ACGIH
Atorvastatin	134523-03-8	TWA	0.05 mg/m ³ (OEB 3)	Internal
		Wipe limit	0.5 mg/100 cm ²	Internal
Ezetimibe	163222-33-1	TWA	25 µg/m ³ (OEB 3)	Internal
		Wipe limit	250 µg/100 cm ²	Internal
Magnesium stearate	557-04-0	NAB	10 mg/m ³	ID OEL
Further information: Not classified as carcinogenic to humans. Not enough data to classify these materials as carcinogenic to humans or animals				
		TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH

- Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
5.1	2023/09/29	26487-00022	Date of first issue: 2014/10/29

protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

- | | | |
|--------------------------|---|--|
| Respiratory protection | : | If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. |
| Filter type | : | Particulates type |
| Hand protection | : | |
| Material | : | Chemical-resistant gloves |
| Remarks | : | Consider double gloving. |
| Eye protection | : | Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols. |
| Skin and body protection | : | Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

9. PHYSICAL AND CHEMICAL PROPERTIES

- | | | |
|-----------------|---|-------------------|
| Appearance | : | powder |
| Colour | : | off-white |
| Odour | : | No data available |
| Odour Threshold | : | No data available |
| pH | : | No data available |

SAFETY DATA SHEET



Ezetimibe / Atorvastatin Formulation



Version 5.1 Revision Date: 2023/09/29 SDS Number: 26487-00022 Date of last issue: 2023/04/04
Date of first issue: 2014/10/29

Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	0.01 g/l
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

10. STABILITY AND REACTIVITY

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
5.1	2023/09/29	26487-00022	Date of first issue: 2014/10/29

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure :

- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity

Not classified based on available information.

Components:**Cellulose:**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg

Atorvastatin:

Acute oral toxicity	:	LD50 (Rat, male and female): > 5,000 mg/kg LD50 (Mouse, male and female): > 5,000 mg/kg
---------------------	---	--

Ezetimibe:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg LD50 (Mouse): > 5,000 mg/kg LD50 (Dog): > 3,000 mg/kg
Acute inhalation toxicity	:	Remarks: No data available
Acute dermal toxicity	:	Remarks: No data available
Acute toxicity (other routes of administration)	:	LD50 (Rat): > 2,000 mg/kg Application Route: Intraperitoneal

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
5.1	2023/09/29	26487-00022	Date of first issue: 2014/10/29

LD50 (Mouse): > 1,000 - < 2,000 mg/kg
Application Route: Intraperitoneal

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:**Atorvastatin:**

Species : Rabbit
Result : No skin irritation

Ezetimibe:

Species : Rabbit
Result : No skin irritation

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Atorvastatin:**

Species : Rabbit
Result : No eye irritation
Method : Draize Test

Ezetimibe:

Species : Rabbit
Result : No eye irritation

Magnesium stearate:

Species : Rabbit
Result : No eye irritation

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
5.1	2023/09/29	26487-00022	Date of first issue: 2014/10/29

Remarks : Based on data from similar materials

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Atorvastatin:**

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Ezetimibe:

Test Type : Maximisation Test
Species : Guinea pig
Result : negative

Magnesium stearate:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : negative
Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:**Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Atorvastatin:

Ezetimibe / Atorvastatin Formulation

Version 5.1 Revision Date: 2023/09/29 SDS Number: 26487-00022 Date of last issue: 2023/04/04
Date of first issue: 2014/10/29

- Genotoxicity in vitro : Test Type: reverse mutation assay
Test system: Salmonella typhimurium
Result: negative
- Test Type: reverse mutation assay
Test system: Escherichia coli
Result: negative
- Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative
- Test Type: sister chromatid exchange assay
Test system: Chinese hamster lung cells
Result: negative
- Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative
- Ezetimibe:**
- Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Metabolic activation: with and without metabolic activation
Result: negative
- Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: negative
- Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative
- Magnesium stearate:**
- Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials
- Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials
- Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Ezetimibe / Atorvastatin Formulation

Version 5.1 Revision Date: 2023/09/29 SDS Number: 26487-00022 Date of last issue: 2023/04/04
Date of first issue: 2014/10/29

Carcinogenicity

Not classified based on available information.

Components:**Cellulose:**

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Atorvastatin:

Species : Mouse, male and female
Application Route : oral (gavage)
Exposure time : 2 Years
NOAEL : 200 mg/kg body weight
LOAEL : 400 mg/kg body weight
Result : negative
Target Organs : Liver

Species : Rat, female
Application Route : oral (gavage)
Exposure time : 2 Years
LOAEL : 100 mg/kg body weight
Target Organs : Musculo-skeletal system

Ezetimibe:

Species : Rat, female
Application Route : oral (feed)
Exposure time : 104 weeks
Result : negative

Species : Rat, male
Application Route : oral (feed)
Exposure time : 104 weeks
Result : negative

Species : Mouse
Application Route : oral (feed)
Exposure time : 104 weeks
Result : negative

Reproductive toxicity

Not classified based on available information.

Components:**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
5.1	2023/09/29	26487-00022	Date of first issue: 2014/10/29

Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Atorvastatin:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, female
Fertility: NOAEL: 225 mg/kg body weight
Result: No effects on fertility

Test Type: Fertility/early embryonic development
Species: Rat, male
Fertility: NOAEL: 175 mg/kg body weight
Result: No effects on fertility

Effects on foetal development : Species: Rat, female
Developmental Toxicity: NOAEL: 20 mg/kg body weight
Result: No teratogenic effects, Embryo-foetal toxicity
Remarks: Maternal toxicity observed.

Species: Rabbit, female
Application Route: Oral
Developmental Toxicity: NOAEL: 100 mg/kg body weight
Result: No embryo-foetal toxicity

Ezetimibe:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, male and female
Fertility: NOAEL: > 1,000 mg/kg body weight
Result: No effects on fertility, No fetotoxicity

Effects on foetal development : Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight
Result: No adverse effects

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight
Result: No adverse effects

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
5.1	2023/09/29	26487-00022	Date of first issue: 2014/10/29

Application Route: Ingestion
 Method: OECD Test Guideline 422
 Result: negative
 Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
 Species: Rat
 Application Route: Ingestion
 Result: negative
 Remarks: Based on data from similar materials

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Liver, muscle) through prolonged or repeated exposure if swallowed.

Components:**Atorvastatin:**

Exposure routes : Ingestion
 Target Organs : Liver, muscle
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Cellulose:**

Species : Rat
 NOAEL : $\geq 9,000$ mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days

Atorvastatin:

Species : Rat, male and female
 LOAEL : 70 mg/kg
 Application Route : oral (gavage)
 Exposure time : 52 Weeks
 Target Organs : Liver

Species : Dog
 LOAEL : 10 mg/kg
 Application Route : oral (gavage)
 Exposure time : 104 Weeks
 Target Organs : Liver

Ezetimibe:

SAFETY DATA SHEET



Ezetimibe / Atorvastatin Formulation



Version 5.1 Revision Date: 2023/09/29 SDS Number: 26487-00022 Date of last issue: 2023/04/04
Date of first issue: 2014/10/29

Species : Dog
NOAEL : 1,000 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 1,500 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 300 mg/kg
Application Route : Oral
Exposure time : 1 yr
Remarks : No significant adverse effects were reported

Magnesium stearate:

Species : Rat
NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Components:

Ezetimibe:

Not applicable

Experience with human exposure

Components:

Atorvastatin:

Ingestion : Symptoms: muscle pain, Fatigue, stomach discomfort, Abdominal pain, constipation, flatulence, liver function change

Ezetimibe:

Ingestion : Symptoms: Headache, Nausea, Vomiting, Diarrhoea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
5.1	2023/09/29	26487-00022	Date of first issue: 2014/10/29

12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Cellulose:**

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l
 Exposure time: 48 h
 Remarks: Based on data from similar materials

Atorvastatin:

Toxicity to fish : LC50 (*Pimephales promelas* (fathead minnow)): > 92 mg/l
 Exposure time: 96 h
 Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): 200 mg/l
 Exposure time: 48 h
 Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (*Pseudokirchneriella subcapitata* (green algae)): 108 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201

NOEC (*Pseudokirchneriella subcapitata* (green algae)): 14 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (*Pimephales promelas* (fathead minnow)): 0.49 mg/l
 Exposure time: 33 d
 Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (*Daphnia magna* (Water flea)): 0.2 mg/l
 Exposure time: 21 d
 Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition

Ezetimibe:

Toxicity to fish : LC50 (*Pimephales promelas* (fathead minnow)): > 0.125 mg/l
 Exposure time: 96 h
 Method: OECD Test Guideline 203
 Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): > 4 mg/l
 Exposure time: 48 h

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
5.1	2023/09/29	26487-00022	Date of first issue: 2014/10/29

		Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.317 mg/l Exposure time: 96 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
		NOEC (Pseudokirchneriella subcapitata (green algae)): 0.317 mg/l Exposure time: 96 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to fish (Chronic toxicity)	:	NOEC (Pimephales promelas (fathead minnow)): 0.051 mg/l Exposure time: 33 d Method: OECD Test Guideline 210
		NOEC (Cyprinodon variegatus (sheepshead minnow)): 4 mg/l Exposure time: 7 d Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0.282 mg/l Exposure time: 21 d Remarks: No toxicity at the limit of solubility
M-Factor (Chronic aquatic toxicity)	:	1
Toxicity to microorganisms	:	EC50: > 4.4 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility
		NOEC: 4.4 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility
Magnesium stearate:		
Toxicity to fish	:	LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EL50 (Daphnia magna (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
5.1	2023/09/29	26487-00022	Date of first issue: 2014/10/29

No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
 Exposure time: 72 h
 Test substance: Water Accommodated Fraction
 Method: OECD Test Guideline 201
 Remarks: Based on data from similar materials
 No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
 Exposure time: 72 h
 Test substance: Water Accommodated Fraction
 Method: OECD Test Guideline 201
 Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l
 Exposure time: 16 h
 Test substance: Water Accommodated Fraction
 Remarks: Based on data from similar materials

Persistence and degradability**Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

Atorvastatin:

Biodegradability : Result: Not readily biodegradable.
 Biodegradation: 7.7 %
 Exposure time: 28 d
 Method: OECD Test Guideline 314

Ezetimibe:

Biodegradability : Result: Not readily biodegradable.
 Biodegradation: 6.8 %
 Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(4.5 d)
 Method: OECD Test Guideline 111

Magnesium stearate:

Biodegradability : Result: Not biodegradable
 Remarks: Based on data from similar materials

SAFETY DATA SHEET



Ezetimibe / Atorvastatin Formulation



Version 5.1 Revision Date: 2023/09/29 SDS Number: 26487-00022 Date of last issue: 2023/04/04
Date of first issue: 2014/10/29

Bioaccumulative potential

Components:

Atorvastatin:

Partition coefficient: n-octanol/water : log Pow: 1.62

Ezetimibe:

Bioaccumulation : Species: *Lepomis macrochirus* (Bluegill sunfish)
Bioconcentration factor (BCF): 173
Exposure time: 97 d
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.36

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

Components:

Atorvastatin:

Distribution among environmental compartments : log Koc: 2.84

Ezetimibe:

Distribution among environmental compartments : log Koc: 4.35
Method: OECD Test Guideline 106

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

SAFETY DATA SHEET



Ezetimibe / Atorvastatin Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
5.1	2023/09/29	26487-00022	Date of first issue: 2014/10/29

N.O.S.
(Ezetimibe, Atorvastatin)

Class	: 9
Packing group	: III
Labels	: 9
Environmentally hazardous	: yes

IATA-DGR

UN/ID No.	: UN 3077
Proper shipping name	: Environmentally hazardous substance, solid, n.o.s. (Ezetimibe, Atorvastatin)
Class	: 9
Packing group	: III
Labels	: Miscellaneous
Packing instruction (cargo aircraft)	: 956
Packing instruction (passenger aircraft)	: 956
Environmentally hazardous	: yes

IMDG-Code

UN number	: UN 3077
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Atorvastatin)
Class	: 9
Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F
Marine pollutant	: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.

Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances Hazardous to Health

Hazardous substances that must be registered : Not applicable

SAFETY DATA SHEET



Ezetimibe / Atorvastatin Formulation



Version 5.1 Revision Date: 2023/09/29 SDS Number: 26487-00022 Date of last issue: 2023/04/04
Date of first issue: 2014/10/29

Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances

Hazardous substances approved for use : Not applicable
Prohibited substances : Not applicable
Restricted substances : Not applicable

Regulation of the Ministry of Trade No. 7 of 2022 on Distribution and Control of Hazardous Materials

Type of hazardous materials subject to distribution and control, Annex I : Not applicable
Type of hazardous materials subject to distribution and control, Annex II : Not applicable

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

16. OTHER INFORMATION

Revision Date : 2023/09/29

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
ID OEL : Indonesia. Occupational Exposure Limits

ACGIH / TWA : 8-hour, time-weighted average
ID OEL / NAB : Long term exposure limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/04/04
5.1	2023/09/29	26487-00022	Date of first issue: 2014/10/29

- International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ID / EN